Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care
نویسندگان
چکیده
INTRODUCTION The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. METHODS Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. RESULTS Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. DISCUSSION The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.
منابع مشابه
Guidelines for brain amyloid imaging published.
O n January 28, SNMMI and the Alzheimer’s Association published online guidance for appropriate use of PET in brain amyloid imaging in suspected Alzheimer disease (AD). These guidelines, which include the first consensus criteria for PET in AD, appear in the current issue of The Journal of Nuclear Medicine (2013;54: 476–490) and in the February issue of Alzheimer’s & Dementia in an article auth...
متن کاملUpdate on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education.
Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate use criteria for amyloid PET as an important tool for increasing th...
متن کاملAmyloid Imaging Coverage with Evidence Development and the IDEAS Study.
B efore the first PET radiopharmaceutical for b-amyloid imaging was approved for marketing by the U.S. Food and Drug Administration in April 2012, the Alzheimer’s Association and SNMMI assembled an Amyloid Imaging Taskforce (AIT), comprising dementia and imaging experts, to review the scientific literature and develop consensus recommendations for clinical use of this promising new technology. ...
متن کاملThe use of amyloid imaging in clinical praxis: a critical review
Recent development in molecular imaging enables measurement of fibrillar amyloid plaque in Alzheimer (AD) brain using positron emission tomography (PET). Three tracers (florbetapir, flutemetamol, florbetaben) have been approved by FDA and EMA for use in clinical assessment of memory impairment to exclude AD. The use of amyloid PET imaging is considered to be appropriate in patients with persist...
متن کاملBarriers in the Performance of Patient's Rights in Iran and Appropriate Offered Solutions Review Article
Abstract Introduction: The goal of patient's rights is to ensure provision of adequate care to patients which in turn enhance the quality of medical care. Objective: The aim of this review article is to evaluate the existing barriers to implementation of patient's rights in Iran and presenting appropriate solutions. Methods: First, all studies related to patient 's bill of rights were ...
متن کامل